FDA Approves APP's Abraxane Paclitaxel Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
American Pharmaceutical Partners will submit survival data and pharmacokinetic data in subjects with hepatic impairment for Abraxane as part of the company's Phase IV commitments. APP hopes to position Abraxane as safer and more effective than Bristol's Taxol and paclitaxel generics.